Overview

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2020-11-13
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
UCB Biopharma SRL